NCT02881216View on ClinicalTrials.gov

Procedural Advantages of a Novel Drug-Eluting Coronary Stent

NACompletedINTERVENTIONAL
Enrollment

814

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

June 30, 2016

Conditions
Coronary Artery Disease
Interventions
DEVICE

Synergy Stent

Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.

DEVICE

Currently common drug-eluting stent (DES)

Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)

All Listed Sponsors
lead

University Hospital Heidelberg

OTHER

NCT02881216 - Procedural Advantages of a Novel Drug-Eluting Coronary Stent | Biotech Hunter | Biotech Hunter